<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2593">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486144</url>
  </required_header>
  <id_info>
    <org_study_id>052020</org_study_id>
    <nct_id>NCT04486144</nct_id>
  </id_info>
  <brief_title>Impact Nerium Oleander on Symptoms and Mortality: A Feasibility Study</brief_title>
  <official_title>Impact of a Proprietary Extract of Nerium Oleander on Symptoms and Mortality :A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthQuilt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Schull Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Hildebrand Fund at the Greater Houston Community Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Maryland, College Park</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthQuilt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the impact of a proprietary extract of Nerium oleander on COVID-19 symptoms and
      mortality in COVID-19 positive patients and their close contacts compared to controls that
      did not receive the extract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an exploratory study based on positive in-vitro, and in-vivo (animals and humans). Up
      to 100 patients that are COVID-19 positive in the ambulatory setting will be invited to
      participate. After informed consent is obtained, patients will be in either the Intervention
      Group (receive extract) or Comparison Group (did not receive extract). A baseline assessment
      and record review will be conducted to assure eligibility criteria. Patients in the
      Intervention Group will be given .5 ml (6.25 mg of extract) every 6 hours for 5 days, total
      of 25 mg per day / 125 mg for 5 days. Patient vital signs (temperature, pulse oximetry, blood
      pressure) and CDC symptoms / side effects will also be tracked. A dedicated medical oversight
      team with 24 / 7 access to care will be provided to monitor safety and tolerance. Patients
      will be followed for 10 days. Baseline antibody, RT-PCR, and live virus will be collected on
      Day 1, Day 5, and Day 10. A Data Monitoring Committee at the Schull Institute will meet
      weekly to review data.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 20, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COVID19 symptoms</measure>
    <time_frame>Every 6 hours for 10 days</time_frame>
    <description>The CDC list of symptoms and &quot;other&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>10 days from enrollment into the Study, e.g. Day 10</time_frame>
    <description>A patient in any arm that dies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>COVID19 Live Virus</measure>
    <time_frame>Day 1, Day 5, Day 10</time_frame>
    <description>COVID19 Live Virus Nasopharyngeal swab performed by UTMB, Texas</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RT-PCR COVID19 Test</measure>
    <time_frame>Day 1, Day 5, Day 10</time_frame>
    <description>RT-PCR Nasopharyngeal swab performed by Fulgent, California</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19 Positive Patient</condition>
  <condition>Covid19 Close Contact</condition>
  <arm_group>
    <arm_group_label>COVID19 Positive: Intervention Group (Receive extract)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These are patients that are COVID19 positive who elect to try the extract.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID19 Positive: Comparison Group (Do NOT receive extract)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These are patients that are COVID19 positive who do NOT elect to try the extract</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID19 Exposed: Intervention Group (Receive extract)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to try the extract.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID19 Exposed: Comparison Group (Do NOT receive extract)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>These are patients that are COVID19 negative at the start, live with a COVID19 positive patient and who elect to NOT try the extract.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Proprietary extract of Nerium oleander</intervention_name>
    <description>This is a proprietary extract of Nerium oleander that is 6.25 ug per 0.5 ml of suspension. It is administered sublingually every six hours for 5 days. The daily dose is 25 ug and the 5 day dose is 125 ug.</description>
    <arm_group_label>COVID19 Exposed: Intervention Group (Receive extract)</arm_group_label>
    <arm_group_label>COVID19 Positive: Intervention Group (Receive extract)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18

          -  COVID 19 positive or close contact of COVID 19 positive

          -  No use of cardiac glycosides or other antiarrhythmic medications

        Exclusion Criteria:

          -  No use of cardiac glycosides or other antiarrhythmic medications

          -  No allergy to coconut oil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Dunn, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>KDunn and Associates, PA dba Healthquilt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KDunn and Associates, PA, dba Healthquilt</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://doi.org/10.1101/2020.07.15.203489</url>
    <description>Plante KS, Plante JA, Fernandez D, et al. Prophylactic and therapeutic inhibition of in vitro SARS-CoV-2 replication by Oleandrin. bioRxiv. July 15, 2020. Cold Spring Harbor Laboratory.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Nerium oleander</keyword>
  <keyword>Clinical symptoms</keyword>
  <keyword>Mortality</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>KDunn and Associates, PA will de-identify data and archive it at The Schull Institute Data Archive at the University of Texas School of Biomedical Informatics.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>October 2020</ipd_time_frame>
    <ipd_access_criteria>Need to have a specific question or plan to study further.</ipd_access_criteria>
    <ipd_url>http://www.theschullinstitute.org</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

